Study guide
9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
Key Takeaways Explain This Topic AI
The ASA Practice Guidelines for Preoperative Fasting specify minimum fasting intervals for healthy patients: 2 hours for clear liquids, 4 hours for breast milk, 6 hours for infant formula / non-human milk / light meal, and 8 hours or more for fried foods, fatty foods, or meat.
Mendelson's syndrome risk is historically defined by a gastric volume >25 mL (>0.4 mL/kg) with a gastric pH <2.5; high-risk populations include patients with diabetic gastroparesis, pregnancy ≥18–20 weeks, acute pain/trauma, bowel obstruction, morbid obesity, and active GLP-1 receptor agonist therapy.
Aspiration prophylaxis pharmacology targets pH and volume: non-particulate antacid (sodium citrate / Bicitra 30 mL PO) acts immediately to buffer gastric acid; H2-antagonists (famotidine 20 mg IV) and PPIs (pantoprazole 40 mg IV) suppress acid secretion over 1–2 hours; prokinetics (metoclopramide 10 mg IV) increase LES tone and accelerate gastric emptying but are contraindicated in mechanical bowel obstruction and Parkinson's disease.
Preoperative chronic medication triage: CONTINUE beta-blockers, statins, clonidine, and thyroid replacement; HOLD ACE inhibitors and ARBs on the morning of surgery to avoid refractory vasoplegic hypotension; HOLD SGLT2 inhibitors (empagliflozin, dapagliflozin) for 3–4 days preoperatively to prevent life-threatening euglycemic diabetic ketoacidosis (euDKA).
GLP-1 receptor agonists (semaglutide, tirzepatide) cause delayed gastric emptying; weekly formulations should be held for 1 week and daily formulations on the day of surgery, with point-of-care gastric ultrasound (POCUS) and rapid sequence induction (RSI) utilized for symptomatic patients or incomplete fasting.
Last updated: August 2026
9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
Pulmonary aspiration of gastric contents is a catastrophic anesthetic complication that can result in chemical pneumonitis, acute respiratory distress syndrome (ARDS), prolonged intensive care, and death. Preventing aspiration requires adherence to evidence-based fasting intervals, identification of delayed gastric emptying risk factors, targeted chemoprophylaxis, and meticulous chronic medication management.
1. ASA Practice Guidelines for Preoperative Fasting (The 2-4-6-8 Rule)
The ASA Fasting Guidelines apply to healthy patients of all ages undergoing elective procedures under general anesthesia, regional anesthesia, or procedural sedation / monitored anesthesia care (MAC). +-------------------------------------------------------------------------+
- | ASA PREOPERATIVE FASTING SUMMARY (2-4-6-8 RULE) |
- +-------------------+-----------------------------------------------------+
- | Fasting Interval | Ingested Material |
- +-------------------+-----------------------------------------------------+
- | 2 Hours | Clear liquids (water, fruit juice without pulp, |
- | | clear tea, black coffee, carbohydrate drinks) |
- | 4 Hours | Ingested breast milk |
- | 6 Hours | Infant formula, non-human milk (cow's milk), |
- | | Light meal (e.g., dry toast and clear liquid) |
- | 8 Hours or more | Fried foods, fatty foods, meat, or heavy meals |
- +-------------------+-----------------------------------------------------+
- Clear Liquids & Gastric Emptying Dynamics
Definition of Clear Liquids: Water, pulp-free fruit juices, carbonated beverages, clear tea, black coffee (without milk, creamers, or dairy substitutes), and clear electrolyte/carbohydrate drinks.
Physiology: Clear liquids follow first-order exponential gastric emptying with a half-life ( t 1 / 2 t_{1/2} t 1/2 ) of approximately 15 − 20 minutes 15 - 20\text{ minutes} 15 − 20 minutes in healthy adults. Ingestion of clear liquids up to 2 hours before induction stimulates gastric peristalsis, clears residual gastric secretions, reduces thirst and anxiety, and results in a lower gastric volume and higher gastric pH compared to prolonged overnight fasting.
Solid Foods: Solids follow zero-order linear emptying requiring mechanical antral trituration to particles < 2 mm <2\text{ mm} < 2 mm before passing the pylorus ( t 1 / 2 ≈ 2 − 4 hours t_{1/2} \approx 2 - 4\text{ hours} t 1/2 ≈ 2 − 4 hours for light meals, > 6 − 8 hours >6-8\text{ hours} > 6 − 8 hours for high-fat or high-protein meals).
Chewing Gum & Hard Candy: Non-caloric chewing gum increases swallowed saliva and gastric secretions but does not significantly increase residual gastric volume or particulate matter. However, flavored/caloric gum or swallowing the gum base warrants clinical caution.
- 2. Pulmonary Aspiration Pathophysiology & Risk Factors
- Mendelson's Syndrome & Critical Thresholds
In 1946, Curtis Mendelson described the syndrome of acute chemical pneumonitis following aspiration of acidic gastric juice during obstetric general anesthesia.
Classic Aspiration Thresholds:
Gastric Fluid Volume: > 25 mL >25\text{ mL} > 25 mL in adults (or > 0.4 mL/kg >0.4\text{ mL/kg} > 0.4 mL/kg ).
Gastric Fluid pH: < 2.5 <2.5 < 2.5 .
Mechanism of Injury: Acidic fluid ( pH < 2.5 \text{pH} < 2.5 pH < 2.5 ) destroys alveolar-capillary membranes, induces severe capillary leak, intra-alveolar hemorrhage, pulmonary edema, bronchospasm, and ventilation-perfusion mismatch. The presence of solid particulate matter compounds this chemical injury with mechanical airway obstruction, foreign-body reaction, necrotizing granulomatosis, and bacterial superinfection.
Conditions Associated with Delayed Gastric Emptying ("Full Stomach")
Clinical Condition Pathophysiological Mechanism of Delayed Emptying
Diabetic Gastroparesis Vagal autonomic neuropathy disrupting normal phase III migrating motor complexes and gastric antral contractions
Pregnancy ( ≥ 18 − 20 weeks \ge 18-20\text{ weeks} ≥ 18 − 20 weeks ) Elevated progesterone relaxes lower esophageal sphincter (LES) tone; mechanical compression of stomach by gravid uterus increases intragastric pressure
Trauma, Acute Pain & Stress Massive sympathetic activation completely halts GI motility and pyloric emptying (gastric contents remain stagnant for hours)
Opioids & Anticholinergics μ \mu μ -opioid receptor agonism in the myenteric plexus inhibits peristalsis; anticholinergics block muscarinic-mediated GI smooth muscle contraction
Gastrointestinal Pathology Mechanical bowel obstruction, ileus, acute peritonitis, active GERD with large hiatal hernia, previous gastrectomy or esophagectomy
GLP-1 Receptor Agonists Potent inhibition of gastric motility and pyloric relaxation (semaglutide, tirzepatide, liraglutide)
Neuromuscular / CNS Parkinson's disease, multiple sclerosis, critical illness polyneuropathy, elevated intracranial pressure
NCE Clinical Rule: Patients with severe trauma or acute pain must be treated as having a full stomach regardless of the time elapsed since their last meal , because emotional and physical trauma completely suspends gastric emptying from the exact moment of injury.
3. Aspiration Prophylaxis Pharmacology
Pharmacologic aspiration prophylaxis aims to decrease gastric fluid volume, increase gastric fluid pH, and increase lower esophageal sphincter (LES) barrier pressure. It is indicated for high-risk patients (obstetric general anesthesia, trauma, severe GERD, gastroparesis, emergency surgery). +-------------------------------------------------------------------------+
- | ASPIRATION CHEMOPROPHYLAXIS AGENTS |
- +-------------------+-----------------------------+-----------------------+
- | Non-Particulate | H2 Antagonists / PPIs | Prokinetics |
- | - Sodium Citrate | - Famotidine 20 mg IV | - Metoclopramide 10 mg|
- | (Bicitra 30 mL) | - Pantoprazole 40 mg IV | IV (increases LES |
- | - Onset: 5-10 min | - Onset: 30-60 min | tone & motility) |
- | - Immediate buffer| - Increases gastric pH >2.5 | - Contra: Obstruction |
- +-------------------+-----------------------------+-----------------------+
- Pharmacologic Profiles of Prophylactic Agents
Drug Class & Agent Dosing & Route Mechanism of Action Clinical Onset & Duration Critical Considerations
Non-Particulate Antacid ; (Sodium Citrate / Citric Acid - Bicitra) 30 mL 30\text{ mL} 30 mL PO ( 0.3 M 0.3\text{ M} 0.3 M solution) Systemic base that directly reacts with and neutralizes existing hydrochloric acid in the stomach Onset: 5 − 10 minutes 5 - 10\text{ minutes} 5 − 10 minutes ; Duration: 1 − 2 hours 1 - 2\text{ hours} 1 − 2 hours Agent of choice for emergency aspiration prophylaxis (e.g., emergent stat cesarean section). Unlike particulate antacids (calcium carbonate, Maalox), non-particulate antacids do not cause destructive foreign-body granulomatous lung injury if aspirated.
H 2 H_2 H 2 -Receptor Antagonist ; (Famotidine) 20 mg 20\text{ mg} 20 mg IV or 20 − 40 mg 20-40\text{ mg} 20 − 40 mg PO Competitive inhibition of histamine H 2 H_2 H 2 receptors on gastric parietal cells, blocking hydrogen ion secretion Onset: 30 − 60 minutes 30 - 60\text{ minutes} 30 − 60 minutes ; Duration: 10 − 12 hours 10 - 12\text{ hours} 10 − 12 hours Increases gastric fluid pH > 2.5 \text{pH} > 2.5 pH > 2.5 and reduces gastric volume. Does not affect acid already present in the stomach.
Proton Pump Inhibitor ; (Pantoprazole) 40 mg 40\text{ mg} 40 mg IV Irreversible inhibition of H + / K + H^+/K^+ H + / K + ATPase enzyme (proton pump) in gastric parietal cells Onset: 1 − 2 hours 1 - 2\text{ hours} 1 − 2 hours ; Duration: > 24 hours >24\text{ hours} > 24 hours Highly effective at suppressing acid secretion, but IV single dose takes 1–2 hours for maximal effect.
Prokinetic Agent ; (Metoclopramide / Reglan) 10 mg 10\text{ mg} 10 mg IV (slow injection over 1 − 2 min 1-2\text{ min} 1 − 2 min ) Dopamine D 2 D_2 D 2 receptor antagonist with 5 -HT 4 5\text{-HT}_4 5 -HT 4 agonist activity; accelerates gastric emptying, stimulates upper GI peristalsis, and increases LES resting tone Onset: 1 − 3 minutes 1 - 3\text{ minutes} 1 − 3 minutes ; Duration: 1 − 2 hours 1 - 2\text{ hours} 1 − 2 hours Contraindicated in mechanical bowel obstruction , GI perforation, pheochromocytoma, and Parkinson's disease. Rapid IV push causes abdominal cramping, akathisia, and acute dystonic reactions (treat extrapyramidal symptoms with diphenhydramine 25 − 50 mg 25-50\text{ mg} 25 − 50 mg IV).
4. Preoperative Medication Management Guidelines
Managing chronic pharmacotherapy requires balancing the risk of medication withdrawal or rebound exacerbation against the risk of adverse drug-anesthetic interactions.
- Chronic Medication Action Matrix +-------------------------------------------------------------------------+
- | PREOPERATIVE MEDICATION ACTION MATRIX |
- +-----------------------------------+-------------------------------------+
- | CONTINUE MORNING OF SURGERY | HOLD PRIOR TO SURGERY |
- +-----------------------------------+-------------------------------------+
- | - Beta-blockers (metoprolol) | - ACEi / ARBs (Hold DOS: vasoplegia)|
- | - Statins (atorvastatin) | - SGLT2i (Hold 3-4 days: euDKA) |
- | - Clonidine (prevent rebound HTN) | - GLP-1 Agonists (Hold day/week) |
- | - Thyroid hormones (levothyroxine)| - Diuretics (Hold DOS) |
- | - Chronic Opioids / Pain meds | - Metformin / Sulfonylureas (DOS) |
- | - Inhaled pulmonary bronchodilators| - DOACs / Warfarin (Protocol-based) |
- | - Antiretrovirals / Immunosuppres | - Nutritional Herbal Supplements (2w)|
- +-----------------------------------+-------------------------------------+
- Detailed Medication Management Protocols
- 1. Cardiovascular Medications
β \beta β -Blockers: CONTINUE. Abrupt withdrawal precipitates severe rebound tachycardia, hypertension, and myocardial ischemia. Patients on chronic beta-blockers must receive their dose on the morning of surgery.
Statins: CONTINUE. Statins stabilize atherosclerotic plaques, suppress endothelial inflammation, and reduce 30-day perioperative cardiac mortality.
Clonidine ( α 2 \alpha_2 α 2 -Agonist): CONTINUE. Abrupt cessation causes massive sympathetic rebound with life-threatening hypertensive crisis.
ACE Inhibitors (Lisinopril, Enalapril) & ARBs (Losartan, Valsartan): HOLD on morning of surgery (12–24 hours prior). Concurrent use of ACEi/ARBs with general or neuraxial anesthesia blocks the renin-angiotensin-aldosterone compensatory response, causing severe refractory vasoplegic hypotension . If vasoplegic hypotension occurs, standard α 1 \alpha_1 α 1 -agonists (phenylephrine) and ephedrine are frequently ineffective; first-line rescue therapy is Vasopressin ( 0.5 − 1.0 unit 0.5 - 1.0\text{ unit} 0.5 − 1.0 unit IV bolus or 0.01 − 0.04 units/min 0.01 - 0.04\text{ units/min} 0.01 − 0.04 units/min infusion) or Methylene Blue ( 1 − 2 mg/kg 1 - 2\text{ mg/kg} 1 − 2 mg/kg IV).
Diuretics (Furosemide, HCTZ): HOLD on morning of surgery to avoid intraoperative hypovolemia, hypotension, and electrolyte disturbances.
2. Endocrine Medications
SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin): HOLD 3 to 4 days prior to surgery. SGLT2 inhibitors block renal proximal tubule glucose reabsorption. During surgical fasting, stress-induced glucagon surge combined with low insulin levels triggers massive lipolysis and ketogenesis, leading to life-threatening Euglycemic Diabetic Ketoacidosis (euDKA) with normal or near-normal blood glucose levels ( < 250 mg/dL <250\text{ mg/dL} < 250 mg/dL ).
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide): Per ASA consensus guidelines:
Hold weekly doses for 1 week prior to elective surgery.
Hold daily doses on the morning of surgery .
If the medication was not held and the patient exhibits GI symptoms (nausea, vomiting, abdominal bloating), delay elective surgery or perform point-of-care gastric ultrasound (POCUS). If stomach is full, proceed with Rapid Sequence Induction (RSI) with cricoid pressure.
Insulin Protocols: Long-acting basal insulin (glargine, detemir, degludec) should be reduced to 50 − 75 % 50 - 75\% 50 − 75% of normal dose the evening before or morning of surgery. HOLD all short-acting / prandial insulin (lispro, aspart, regular) while the patient is fasting.
Oral Hypoglycemics: Hold metformin on the morning of surgery (risk of lactic acidosis in hypoperfusion/renal injury). Hold sulfonylureas (glipizide, glyburide) on morning of surgery (risk of hypoglycemia).
Chronic Corticosteroids: Patients receiving > 5 mg/day >5\text{ mg/day} > 5 mg/day prednisone equivalent for > 3 weeks >3\text{ weeks} > 3 weeks within the past year have potential hypothalamic-pituitary-adrenal (HPA) axis suppression. Administer "stress-dose" hydrocortisone: Minor surgery ( 25 mg 25\text{ mg} 25 mg IV), Moderate surgery ( 50 mg 50\text{ mg} 50 mg IV), Major surgery ( 100 mg 100\text{ mg} 100 mg IV q8h for 24h).
3. Anticoagulants & Antiplatelets
Warfarin: Hold for 5 days prior; verify INR ≤ 1.4 − 1.5 \le 1.4 - 1.5 ≤ 1.4 − 1.5 for surgery or neuraxial puncture.
Direct Factor Xa Inhibitors (Apixaban / Eliquis, Rivaroxaban / Xarelto): Hold 24 − 48 hours 24 - 48\text{ hours} 24 − 48 hours for standard surgery with normal renal function; hold 48 − 72 hours 48 - 72\text{ hours} 48 − 72 hours for high bleeding risk surgery or neuraxial anesthesia.
Direct Thrombin Inhibitor (Dabigatran / Pradaxa): Hold 24 − 48 hours 24 - 48\text{ hours} 24 − 48 hours ( C r C l > 50 mL/min CrCl > 50\text{ mL/min} C r Cl > 50 mL/min ) or 72 − 96 hours 72 - 96\text{ hours} 72 − 96 hours ( C r C l < 50 mL/min CrCl < 50\text{ mL/min} C r Cl < 50 mL/min ).
P2Y12 Antiplatelet Inhibitors: Clopidogrel (hold 5 to 7 days ), Ticagrelor (hold 5 days ), Prasugrel (hold 7 days ).
5. Preoperative Premedication & Anxiolysis
Midazolam ( 1 − 2 mg 1 - 2\text{ mg} 1 − 2 mg IV): Rapid-acting GABA A \text{GABA}_A GABA A receptor positive allosteric modulator providing potent anxiolysis and anterograde amnesia without analgesia. Exercise extreme caution in elderly patients and those with severe OSA.
Glycopyrrolate ( 0.1 − 0.2 mg 0.1 - 0.2\text{ mg} 0.1 − 0.2 mg IV): Quaternary ammonium anticholinergic that does not cross the blood-brain barrier (no central anticholinergic syndrome). Potent antisialagogue used prior to awake fiberoptic intubation or ketamine administration.
Multimodal Pre-emptive Analgesia: Oral administration of acetaminophen ( 1000 mg 1000\text{ mg} 1000 mg PO), gabapentin ( 300 − 600 mg 300 - 600\text{ mg} 300 − 600 mg PO), and celecoxib ( 200 − 400 mg 200 - 400\text{ mg} 200 − 400 mg PO) 1–2 hours prior to incision significantly decreases intraoperative volatile anesthetic and postoperative opioid requirements.